”Innovative pioneer in microbiome therapeutics.”
We are fascinated by the connection between gut health and many health problems. That is why we have developed innovative microbiome solutions through science to support the management of chronic functional diseases.
About Us
MY HEALTH Belgian Biotech Company, is a leading clinical-stage healthcare company specializing in Microbiome solutions. Our focus is on pioneering breakthroughs to enhance the well-being of individuals by preventing and alleviating functional diseases associated with the Microbiome.
We've achieved an important milestone by publishing the first probiotic study in LANCET Gastroenterology & Hepatology. The study demonstrated positive results in addressing Functional Dyspepsia through the use of our proprietary strains, MY01 and MY02, which stand out in the market due to their unique features, offering a competitive edge over existing alternatives.
Moreover, our dedicated R&D team is consistently exploring new avenues to meet patient needs, particularly in the realm of the gut-brain axis. Through ongoing research, we aim to contribute to advancements in various disease fields, further solidifying our commitment to improving the well-being of individuals.
Our Specialty
We specialize in Functional Dyspepsia, which shows high disease prevalence and growing disease awareness.
Recent studies showed that there is a 7% global prevalence of Functional Dyspepsia, based on the definition of the Rome III and Rome IV criteria¹.
Our Strength- Sporebiotics
Sporebiotics are a new generation of bacteria validated by Belgian scientists.
Our Proprietary Strains: MY01 & MY02
They have the unique ability to form spores. In the form of spores, these bacteria are extremely resistant to high temperature, humidity, stomach acid and bile salts. They can be stored for a very long time and have an excellent survivability through the stomach to the small intestine.
Key Feature
Sporebiotics high stability allows it to be combined with other effective ingredients. Unlike the traditional probiotics, which are difficult to be combined with other ingredients because of their vulnerability.
Our Research
Our spore-forming probiotics’ latest publication in LANCET Gastroenterology & Hepatology
First randomized, double-blind, placebo-controlled probiotics trial in dyspepsia.
Our proprietary strains: MY01 & MY02 (Spore-forming probiotics) can be considered as monotherapy or as add-on to proton-pump inhibitors in patients with functional dyspepsia with refractory symptoms.
Click here to listen to The Lancet Podcast “In conversation with” about our clinical trial.
Our Future
In 2022, we started our research project on women health because many women in the world have been suffering from VVC for a long time, MY HEALTH would like to contribute its efforts and is looking forward to sharing the research results in the near future with you.
Our Production
All of our products are produced in GMP (Good Manufacturing Practice) certified facilities located in Belgium and the Netherlands.
We are looking for new partners worldwide!
DUOSPORE is available in the following countries and we are actively looking for partners in other countries
Reference
¹Sperber, A. D., Bangdiwala, S. I., Drossman, D. A., Ghoshal, U. C., Simren, M., Tack, J., Whitehead, W. E., Dumitrascu, D. L., Fang, X., Fukudo, S., Kellow, J., Okeke, E., Quigley, E. M., Schmulson, M.,Whorwell, P., Archampong, T., Adibi, P., Andresen, V., Benninga, M. A., . . . Palsson, O. S. (2021b). Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology, 160(1), 99–114.e3. https://doi.org/10.1053/j.gastro.2020.04.014
We use cookies to improve your experience and to help us understand how you use our site. Please refer to our cookie notice and privacy policy for more information regarding cookies and other third-party tracking that may be enabled.
